Merck & Co., Inc.

XNYSHealth care

Last traded price · USD

$150.77

+4.22%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:30 IST · A quote does not mean the product is available to trade on your account.

Day's open: $148.54
Previous close: $144.67
Volume: 10.7M
Day's high: $150.42
Day's low: $146.05

In brief

Merck & Co., Inc. is a health care company listed on the New York Stock Exchange, valued at about $371.98B.
Its shares closed at $150.36 on 4 Nov 2026, up 79.3% over the past year.
From India you can buy MRK in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Merck & Co., Inc. (MRK) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole MRK share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade MRK options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: +5.9% (SPY −1.6%, XLV +13.5%). 3 months: +17.2% (SPY −0.4%, XLV +15.5%). 1 year: +79.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: MRK, SPY and XLV · as of 4 Nov 2026
P/E 3.0× its peers' median
Trailing P/E of 120.6 against a median of 40.5 across 5 peers named in its company record (range 13.7 to 80.8).
Quote feed P/E (price ÷ trailing 12-month EPS); peers as named in the company record · as of 4 Nov 2026
4.2% below its 52-week high
Closed at $150.36 on 4 Nov 2026: 4.2% below the 52-week high of $156.92 (25 Aug 2026) and 78.3% above the low of $84.35 (6 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $150.36 was 2.6% above its 50-day average ($146.54) and 18.1% above its 200-day average ($127.28). It has closed above the 200-day for 251 sessions, since 5 Nov 2025. The 50-day average crossed above the 200-day on 30 Oct 2025, 254 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Short interest at 1.1% of shares outstanding
26.8M shares were sold short at the 15 Oct 2026 settlement, 1.1% of the 2.47B shares outstanding; covering them would take 3.0 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+5.9%

6 months+32.4%

1 year+79.3%

5 years+66.1%

Newswire

About

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).

Website

Notable moves

August 19, 2026
+12.60%
July 30, 2024
−9.81%
November 5, 2021
−9.86%

Merck & Co., Inc.

XNYSHealth care

Last traded price · USD

$150.77

+4.22%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:30 IST · A quote does not mean the product is available to trade on your account.

Day's open: $148.54
Previous close: $144.67
Volume: 10.7M
Day's high: $150.42
Day's low: $146.05

In brief

Merck & Co., Inc. is a health care company listed on the New York Stock Exchange, valued at about $371.98B.
Its shares closed at $150.36 on 4 Nov 2026, up 79.3% over the past year.
From India you can buy MRK in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Merck & Co., Inc. (MRK) shares from India?

Do I need the price of a whole MRK share to invest?

How much can I invest in US stocks in a year?

Can I trade MRK options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: +5.9% (SPY −1.6%, XLV +13.5%). 3 months: +17.2% (SPY −0.4%, XLV +15.5%). 1 year: +79.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: MRK, SPY and XLV · as of 4 Nov 2026
P/E 3.0× its peers' median
Trailing P/E of 120.6 against a median of 40.5 across 5 peers named in its company record (range 13.7 to 80.8).
Quote feed P/E (price ÷ trailing 12-month EPS); peers as named in the company record · as of 4 Nov 2026
4.2% below its 52-week high
Closed at $150.36 on 4 Nov 2026: 4.2% below the 52-week high of $156.92 (25 Aug 2026) and 78.3% above the low of $84.35 (6 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $150.36 was 2.6% above its 50-day average ($146.54) and 18.1% above its 200-day average ($127.28). It has closed above the 200-day for 251 sessions, since 5 Nov 2025. The 50-day average crossed above the 200-day on 30 Oct 2025, 254 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Short interest at 1.1% of shares outstanding
26.8M shares were sold short at the 15 Oct 2026 settlement, 1.1% of the 2.47B shares outstanding; covering them would take 3.0 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+5.9%

6 months+32.4%

1 year+79.3%

5 years+66.1%

Newswire

About

Website

Notable moves

August 19, 2026
+12.60%
July 30, 2024
−9.81%
November 5, 2021
−9.86%

Merck & Co., Inc.

Merck & Co., Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

P/E 3.0× its peers' median

4.2% below its 52-week high

Above its 50- and 200-day averages

Short interest at 1.1% of shares outstanding

Merck & Co., Inc.

Merck & Co., Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

P/E 3.0× its peers' median

4.2% below its 52-week high

Above its 50- and 200-day averages

Short interest at 1.1% of shares outstanding